Description

This session will highlight how technologic advances have improved therapeutic gain in radiation oncology and how these advances may be combined with biologic advances to further move the field forward and improve the outcomes and quality of life of patients undergoing radiation therapy. The session will address how new technologies have improved outcomes and reduced toxicities resulting in a therapeutic gain.   

Subspecialties: MI, RO
Modalities: CT

Speaker(s):

• Bruce Haffty, MD, FACR
• Richard Hoppe, MD, FACR
• Brian Kavanagh, MD, MPH
• Mitchell Machtay, MD

Disclosures

• Mitchell Machtay, MD : Honoraria: Bristol-Myers Squibb, Eli Lily and Company,  Abbvie; Stock Options: Merck Oncology